On the contrary, no association between CCL2-2518A/G and gynecological cancer risk was noted in the AA vs AG + GG (OR = 0.87, 95%CI = 0.65–1.16, P > 0.05), AA vs AG (OR = 1.01, 95%CI = 0.83–1.23, P > 0.05), and A vs G (OR = 0.83, 95%CI = 0.68–1.02, P > 0.05) models (Table 3). This evidence concerns the gene CCL2 and female reproductive organ cancer.